Free Trial
NASDAQ:QNCX

Quince Therapeutics Q2 2024 Earnings Report

Quince Therapeutics logo
$1.05 -0.04 (-3.67%)
Closing price 05/6/2025 04:00 PM Eastern
Extended Trading
$1.01 -0.04 (-3.33%)
As of 05:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quince Therapeutics EPS Results

Actual EPS
-$0.18
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Quince Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quince Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Monday, August 12, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

Quince Therapeutics' Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Sunday, May 11, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Quince Therapeutics Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92% win rate trading system is built to profit in any market – whether Bitcoin is mooning, correcting, or chopping sideways. No more guessing. No more stress. Just precision trades that put you in control.
See More Quince Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quince Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quince Therapeutics and other key companies, straight to your email.

About Quince Therapeutics

Quince Therapeutics (NASDAQ:QNCX), a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

View Quince Therapeutics Profile

More Earnings Resources from MarketBeat